
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp demonstrates a positive outlook due to its effective immunogenicity and tolerability results for its vaccine candidates, notably showing favorable vaccine response rates for the shingles vaccine compared to Shingrix. The company's focus on enhancing immune response through its Toll-like Receptor Immune Modulation Platform underscores its potential for significant advancements in the vaccine market. Additionally, consistent revenue generation from its existing products, such as CpG 1018 and the HEPLISAV-B vaccine, supports the financial stability and growth prospects of the company.
Bears say
Dynavax Technologies faces significant risks in the efficacy and safety of its product candidates in clinical development, which could hinder their approval and commercialization prospects. The company also encounters challenges related to effective commercialization due to competitive market conditions, internal issues, and potential litigation risks. Additionally, Dynavax’s ability to successfully partner its candidates may be compromised by unfavorable terms, further jeopardizing its commercial launch success and overall financial outlook.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares